NCT04452955 - A Study to Assess Safety and Efficacy of PRL3-Zumab in Patients with Solid Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 12, 2020

Primary Completion Date

November 1, 2025

Study Completion Date

December 1, 2025

Conditions

Solid Tumor

Interventions

BIOLOGICAL

PRL3-zumab

Starting dose of 6 mg/kg will be administered as IV infusion over 60 minutes every 2 weeks (±2 days)

Trial Locations (5)

Norton Healthcare, Louisville

HonorHealth Research, Scottsdale

Comprehensive Cancer Centers of Nevada, Las Vegas

The Angeles Clinic, Los Angeles

St. Jude Medical Center, Fullerton